论文部分内容阅读
《欧盟运行条约》第102条虽然规定了禁止滥用市场力的行为,但并没有给出市场力滥用行为的法律定义及其明确的认定标准,而是仅仅在第l句对行为进行概括性描述,之后在第2句列举了几种典型的市场力滥用行为。因此在适用第102条认定市场力滥用行为时,需要欧盟委员会和司法实践预先确立一个分析标准。然而,实践中是否真正存在这样一个普适性的分析标准呢?如何确立这样的分析标准?本文拟从第102条的内容以及对于滥用行为的认定现状入手,结合医药领域对市场力滥用行为的认定,分析确立普适性标准的可行性,并就创新保护与自由竞争保护之间的紧张关系提出看法。
Article 102 of the Treaty on the Treaty on the Treaty on Operation of the European Union, although it provides for a prohibition on the abuse of market power, does not give any legal definition of market abuse and its clearly established standard of determination. Rather, it merely summarizes the conduct in the first sentence , Followed by the second sentence listing several typical market abuse abuses. Therefore, the application of Article 102 to determine the abuse of market power requires the European Commission and judicial practice to establish an analytical standard in advance. However, in practice, is there such a universally applicable analytical standard? How to establish such an analytical standard? This article intends to start with the substance of Article 102 and the status quo of identification of abusive behavior, combining with the abuse of market power in the medical field Identify and analyze the feasibility of establishing pervasive standards and comment on the tension between innovation protection and free competition protection.